Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

(2019) M V Dieci et al.   ANNALS OF ONCOLOGY

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

(2018) S Venkatesan et al.   ANNALS OF ONCOLOGY

Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study

(2018) S Loi et al.   CANCER RESEARCH

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

(2018) Juan Miguel Cejalvo et al.   CANCER TREATMENT REVIEWS

Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype

(2018) Jeremy Force et al.   Clinical Breast Cancer

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

(2018) Jian Li et al.   Journal of Hematology & Oncology

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

(2018) Michail Ignatiadis et al.   JNCI-Journal of the National Cancer Institute

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

(2018) Carsten Denkert et al.   LANCET ONCOLOGY

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

(2018) Michail Ignatiadis et al.   JNCI-Journal of the National Cancer Institute

De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.

(2018) Valentina Guarneri et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

(2017) Ander Urruticoechea et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

(2017) Stephen J Luen et al.   LANCET ONCOLOGY

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

(2017) Antonio Llombart-Cussac et al.   LANCET ONCOLOGY

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Miguel Martin et al.   LANCET ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

(2017) Carlos R. Gil Del Alcazar et al.   Cancer Discovery

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

(2017) Aura Muntasell et al.   Frontiers in Immunology

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

(2017) Patrick G. Gavin et al.   JAMA Oncology

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy

(2017) Debora Fumagalli et al.   JAMA Oncology

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer

(2017) Shuzhen Liu et al.   JAMA Oncology

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

(2016) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status

(2016) Yul Ri Chung et al.   BREAST CANCER RESEARCH AND TREATMENT

NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells

(2016) John O. Richards et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

(2016) Maria Vittoria Dieci et al.   CANCER TREATMENT REVIEWS

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

(2016) B. Ingold Heppner et al.   CLINICAL CANCER RESEARCH

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

(2016) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

(2016) Gábor Tóth et al.   mAbs

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer

(2016) A Musolino et al.   PHARMACOGENOMICS JOURNAL

Tumor Cell–Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells

(2016) Nikolaos Svoronos et al.   Cancer Discovery

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

(2016) Edith A. Perez et al.   JAMA Oncology

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer

(2016) Jashodeep Datta et al.   JAMA Oncology

Immuno-oncology combinations: raising the tail of the survival curve

(2016) Samuel J. Harris et al.   Cancer Biology & Medicine

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

(2015) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

(2015) Seong-Rim Kim et al.   CANCER RESEARCH

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

(2015) L. G. Lum et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

(2015) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade

(2015) Philipp Müller et al.   Science Translational Medicine

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition

(2015) Martina Di Modica et al.   Oncotarget

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

(2015) Roberto Salgado et al.   JAMA Oncology

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

(2015) Alexandra Canonici et al.   Oncotarget

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity

(2014) Kea Martin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

(2014) A. Prat et al.   CLINICAL CANCER RESEARCH

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Oncogene addiction and immunity

(2014) Peter Savas et al.   CURRENT OPINION IN ONCOLOGY

The immune system and response to HER2-targeted treatment in breast cancer

(2014) Giampaolo Bianchini et al.   LANCET ONCOLOGY

Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells

(2014) P. Muller et al.   Cancer Immunology Research

Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

(2013) A. K. Dunbier et al.   CLINICAL CANCER RESEARCH

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

(2013) Lára Hannesdóttir et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

(2013) Srinivas Mamidi et al.   Molecular Oncology

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

(2013) Steven A Roberts et al.   NATURE GENETICS

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

(2013) Yasmin Issa-Nummer et al.   PLoS One

Analysis of Fc  Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

(2012) S. A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models

(2011) Y. Yamashita-Kashima et al.   CLINICAL CANCER RESEARCH

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

(2011) Sylvain Ladoire et al.   JOURNAL OF PATHOLOGY

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast

(2010) Henry M. Kuerer et al.   CANCER

Anti-HER2 vaccines: new prospects for breast cancer therapy

(2010) Maha Zohra Ladjemi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

(2008) S. Ladoire et al.   CLINICAL CANCER RESEARCH

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE